Clinical trial · Interventional
Simvastatin Effect on Radiation Therapy of Brain Metastases
The Effect of Simvastatin on the Clinical Outcome of Patients With Brain Metastases Treated With Radiation Therapy: a Pilot Study
NCT02104193CI-TRIAL-00020963completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to evaluate the effect of simvastatin in combination with radiotherapy on the clinical outcomes of patients with brain metastases.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Metastases | Brain Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| radiation therapy | Radiation | — | UNRESOLVED |
| simvastatin in addition to radiation therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- simvastatin
- description
- they will receive simvastatin in addition to radiation therapy
- interventionNames
- Drug: simvastatin in addition to radiation therapy
- type
- ACTIVE_COMPARATOR
- label
- control
- description
- they will receive radiation therapy only
- interventionNames
- Radiation: radiation therapy
Primary outcomes (1)
- measure
- a- Response rate
- timeFrame
- 4 weeks after radiation therapy
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with measurable brain metastases * Age more than 18 years old * Patients should be planned for radiation therapy Exclusion Criteria: * Renal dysfunction (more than 1 upper normal level) * Hepatic dysfunction (alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) \>3 times the upper normal level ) * Pregnancy or lactation. * Known hypersensitivity to simvastatin
References
Publications (0)
Data not yet available
No reference posted for this study.